Artes Medical announces enrollment reached for post-marketing study of ArteFill

November 4, 2008

San Diego - Artes Medical has announced enrollment is completed in the 1,000-patient post-marketing study required by the Food and Drug Administration for ArteFill, the only FDA-approved non-resorbable dermal filler, according to Business Wire.

San Diego - Artes Medical has announced enrollment is completed in the 1,000-patient post-marketing study required by the Food and Drug Administration for ArteFill, the only FDA-approved non-resorbable dermal filler, according to Business Wire.

Study participants will be assessed for long-term nasolabial fold reduction and the safety profile of ArteFill over a five-year period. They will also rate their satisfaction with the treatment.